Literature DB >> 7931156

The herpes simplex virus type 1 origin-binding protein interacts specifically with the viral UL8 protein.

G W McLean1, A P Abbotts, M E Parry, H S Marsden, N D Stow.   

Abstract

The products of herpes simplex virus type 1 (HSV-1) genes UL5, UL8 and UL52 form a complex in virus-infected cells that exhibits both DNA helicase and DNA primase activities. UL8 protein was purified from insect cells infected with a recombinant baculovirus and used to generate monoclonal antibodies (MAbs). MAb 0811 was shown to recognize the UL8 protein in both Western blots and immunoprecipitation assays and to co-precipitate the other two proteins in the complex from insect cells triply infected with recombinants expressing the UL5, UL8 and UL52 polypeptides. Experiments performed using extracts from doubly infected cells indicated that UL8 could interact separately with both the UL5 and UL52 proteins. Similar experiments using a recombinant virus that expressed the HSV-1 origin-binding protein (OBP), UL9, demonstrated a direct physical interaction between the helicase-primase complex and OBP which involved the UL8 subunit. The C-terminal DNA-binding domain of OBP is dispensable for this interaction, as evidenced by the ability of MAb 0811 to co-precipitate a truncated UL9 protein, containing only the N-terminal 535 amino acids, with UL8.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7931156     DOI: 10.1099/0022-1317-75-10-2699

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  44 in total

1.  Leading and lagging strand DNA synthesis in vitro by a reconstituted herpes simplex virus type 1 replisome.

Authors:  M Falkenberg; I R Lehman; P Elias
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

2.  Origin binding protein-containing protein-DNA complex formation at herpes simplex virus type 1 oriS: role in oriS-dependent DNA replication.

Authors:  J A Isler; P A Schaffer
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Reconstitution of recombination-dependent DNA synthesis in herpes simplex virus 1.

Authors:  Amitabh V Nimonkar; Paul E Boehmer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-19       Impact factor: 11.205

4.  The Epstein-Barr virus replication protein BBLF2/3 provides an origin-tethering function through interaction with the zinc finger DNA binding protein ZBRK1 and the KAP-1 corepressor.

Authors:  Gangling Liao; Jian Huang; Elizabeth D Fixman; S Diane Hayward
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  DNA binding activity of the herpes simplex virus type 1 origin binding protein, UL9, can be modulated by sequences in the N terminus: correlation between transdominance and DNA binding.

Authors:  Soma Chattopadhyay; Sandra K Weller
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Direct interaction between the N- and C-terminal portions of the herpes simplex virus type 1 origin binding protein UL9 implies the formation of a head-to-tail dimer.

Authors:  Soma Chattopadhyay; Sandra K Weller
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 7.  Replication and recombination of herpes simplex virus DNA.

Authors:  Isabella Muylaert; Ka-Wei Tang; Per Elias
Journal:  J Biol Chem       Date:  2011-03-01       Impact factor: 5.157

8.  Properties of the novel herpes simplex virus type 1 origin binding protein, OBPC.

Authors:  K Baradaran; M A Hardwicke; C E Dabrowski; P A Schaffer
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

9.  Use of transdominant mutants of the origin-binding protein (UL9) of herpes simplex virus type 1 to define functional domains.

Authors:  A K Malik; S K Weller
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

10.  Herpes simplex ICP27 mutant viruses exhibit reduced expression of specific DNA replication genes.

Authors:  S L Uprichard; D M Knipe
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.